Rilpivirine/Tenofovir/Emtricitabine (Complera)

Overview | News & Research

Overview

Prescribing Information for Rilpivirine/Tenofovir/FTC (Complera) (PDF) (January 2013)
From Gilead Sciences, Inc.
Approval of Complera: Emtricitabine/Rilpivirine/Tenofovir DF Fixed-Dose Combination (August 10, 2011)
From U.S. Food and Drug Administration

News & Research

Complera Labeling Update: No Longer Recommended at High Viral Loads; Hepatotoxicity Precaution Added (January 28, 2013)
From U.S. Food and Drug Administration
HIV Drug Updates (September/October 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Switching From Protease Inhibitor to Complera Maintains Viral Suppression, Lowers Lipids (August 3, 2012)
From HIVandHepatitis.com
The Path to a Cure (January/February 2012)
The pathway to an HIV cure and other treatments in the pipeline.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Switching From Atripla to Complera (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Complera and Atripla News (January/February 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
Top 10 HIV/AIDS-Related Clinical Developments of 2011 (December 1, 2011)
David Alain Wohl, M.D., on HIV treatment as prevention; the dawning of pre-exposure prophylaxis (PrEP), but with women absent; the concept of "viremia copy-years"; the impact of race and gender on HIV treatment outcomes; setbacks for two treatment approaches involving Isentress; new hepatitis C therapies; a new once-daily HIV pill; the rising rates of HIV among black MSM; and what comes after "test and treat."
From TheBody.com
Switching from Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Single Tablet Regimen (STR) to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) STR in Virologically Suppressed, HIV-1 Infected Subjects (September 21, 2011)
From National AIDS Treatment Advocacy Project
Switching From Atripla to Complera Safe and Effective in 12-Week Study (September 21, 2011)
From National AIDS Treatment Advocacy Project
FDA Approve New NNRTI-Based Fixed-Dose Combination of Rilpivirine/Tenofovir/FTC (Complera) in the U.S. (July/August 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
FDA Approves the New Full-Regimen HIV Pill Complera (August 12, 2011)
From Project Inform
U.S. Food and Drug Administration Approves Gilead's Once-Daily HIV Pill Complera (August 11, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Next Single-Pill HIV Treatment Approved, and It's Not Called "B-Tripla" (August 11, 2011)
What's most important to know about Complera, the newest all-in-one HIV medication? Paul Sax, M.D., breaks it down.
From Journal Watch

MOST VIEWED ARTICLES

	Scientists Crack HIV's Coating
	HIV Management Today: Cardiovascular Risk Management in HIV Care: Facing Reality
	Enough With the HIV Treatment Cascade Research, Let's Do Something About It Already: A Blog Entry by Lisa Fitzpatrick, M.D., M.P.H.
	HIV Eradication Moves One Small Step Closer as Stem Cell Transplant Findings Titillate
	New Danish Results Spark Interest for Future HIV Cure Research
	Liquid Injectable Silicone Effective, Safe for Treating HIV Patients With Facial Lipoatrophy: Study

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.